4/1/2015 – Sarepta Therapeutics was given a new $45.00 price target on by analysts at Oppenheimer. They now have a “buy” rating on the stock.
3/2/2015 – Sarepta Therapeutics had its price target lowered by analysts at Needham & Company LLC from $52.00 to $38.00. They now have a “buy” rating on the stock.
Hopefully soon this will be chicken feed numbers.
It seems to me one of these patents are second generation antisense for exon skipping and the other''sarepta's third generation antisense.I do not see why one could patent the whole exon skipping package unless they listed all the drugs that could be used in that patent and examples included.The exon skipping drug itself would be the patent .'' One would be Exon skipping with 2'ome and the other Exon skipping with pmo-s.........
Both patents are different because they are specific in the drugs used in exon skipping
This was 2009 ,many more after this...
A patent estate including 222 patents (domestic and foreign) issued or licensed to us, and 196 pending patent applications (domestic and foreign) has been developed for purposes of protecting our technologies. We intend to protect our proprietary technology with additional filings as appropriate.
So very correct..rna patent is not exon skipping patent and pmo-s being a improvement 'trumps other patents'' example ''sarepta third generation antisense '' most all others are second generation antisense''
Duchenne muscular dystrophy patients treated with GlaxoSmithKline's (GSK - Get Report) experimental drug drisapersen have been hospitalized due to kidney toxicity and low platelet counts, according to a Glaxo scientist who spoke at a research meeting in Rome last Sunday.
Glaxo has disclosed some safety data from early-stage drisapersen clinical trials previously, mainly related to moderate cases of proteinuria (excess protein in the urine) and decreased thrombocytes, which play a role in blood clotting. However, the significance of the adverse events attributed to drisapersen, also known as GSK-2402968, escalated with Sunday's disclosure of hospitalized patients.
Dr. Rohit Batta, global medical leader in Glaxo's neuromuscular rare disease unit, said four Duchenne muscular dystrophy (DMD) patients treated with drisapersen required hospitalization due to thrombocytopenia and that "several" patients with "severe proteinuria" also required hospitalization.
add all other exons for dmd 3.5 billion yearly. so if you go 5 times yearly sales for Sarepta for a buyout what would you get?If you oly did exon 51 times 5 = 5 billion....sale
with upfront cash and 30 percent of proceeds
Application number: 20150080311
Abstract: An antisense compound for use in treating myotonic dystrophy DM1 or DM2, a method of enhancing antisense targeting to heart and quadricep muscles, and a method for treating DM1 or DM2 in a mammalian subject are disclosed. The oligonucleotide has 8-30 bases, with at least 8 contiguous bases being complementary to the polyCUG or polyCCUG repeats in the 3?UTR region of dystrophia myotonica protein kinase (DMPK) mRNA in DM1 or DM2, respectively. Conjugated to the oligonucleotide is a cell-penetrating peptide having the sequence (RXRR(B/X)R)2XB, where R is arginine; B is ?-alanine; and each X is —C(O)—(CH2)n—NH—, where n is 4-6. The antisense compound is effective to selectively block the sequestration of muscleblind-like 1 protein (MBNL1) and/or CUGBP, in heart and quadricep muscle in a myotonic dystrophy animal model.
Filed: April 24, 2014
Issued: March 19, 2015
Assignee: Sarepta Therapeutics, Inc.
Inventors: Hong M. Moulton, Ryszard Kole
Will not need monies if approved this year...200 mil in bank....would like to see a partner on other md diseases with cash upfront..likely..
LOOKS LIKE END OF MAY DATA COLLECTION TO ME..
Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients with Duchenne Muscular Dystrophy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 12, 2014-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of RNA-based therapeutics, today announced that it has initiated dosing in a clinical study of eteplirsen, the Company's lead exon-skipping therapeutic candidate for the treatment of Duchenne muscular dystrophy (DMD), in patients who are non-ambulant or who have advanced DMD and don't meet a minimum 6-minute walk test score at baseline.
The open-label study, 4658-204 (Study 204), will include approximately 20 patients treated with eteplirsen who have genotypes amenable to exon 51 skipping and who meet other study inclusion criteria. The study will be conducted at several sites in the United States and is designed to evaluate the safety of eteplirsen in DMD patients over 96 weeks of dosing. Patients enrolled in the study will receive once weekly intravenous infusions of 30mg/kg of eteplirsen, and data will be collected across a number of safety parameters and secondary efficacy endpoints.
BEFORE ANY PRODUCTION NEWS. DATE?
Chris was dictating to the fda and not listening to them and also the fda thought chris was behind the petition ,parent groups ect. It was severe pressure from large stock holders and the fda.bottom line''chris got personally involved. the drug works better then any in the pipeline.
need substance like ''biopsy results or validation on anything ,i know for sure it is no new trial data info until 24weeks. IT SEEMS sAREPTA MAY BE SOLD I DO THINK.